AEON Biopharma Shares Surge in Pre-Market Trading
AEON Biopharma (NYSE American: AEON) shares are jumping nearly 50% in pre-market trading on Wednesday, September 10, 2026, following the publication of encouraging new study results for the company's lead drug candidate.
Catalyst: Positive Forced Degradation Study Results
The catalyst for the pre-market surge appears to be AEON Biopharma's September 9 announcement that its pilot forced degradation study produced positive results supporting the analytical comparability of ABP-450 to BOTOX, the widely-used neuromodulator marketed by AbbVie subsidiary Allergan.
Forced degradation studies are controlled experiments that expose a drug substance or product to stressful conditions such as heat, light, and humidity. These studies help determine how a molecule breaks down over time and whether its degradation profile matches that of the reference product. Positive results in this type of study are an important step in demonstrating biosimilarity to regulators.
What Is ABP-450?
ABP-450 is AEON Biopharma's 900 kDa botulinum toxin complex being developed as a potential biosimilar to BOTOX. The company is pursuing therapeutic indications including chronic migraine, cervical dystonia, and gastroparesis.
Demonstrating that ABP-450 behaves comparably to BOTOX is central to AEON's regulatory strategy. The drug works by blocking nerve signals to muscles, temporarily reducing muscle activity. BOTOX itself generates billions of dollars in annual sales for AbbVie.
Volume and Price Action
AEON shares last traded at $0.36, up 49.88% from the previous regular-session close of $0.2402. More than 48.5 million shares have changed hands in the pre-market session, compared to an average daily volume of roughly 343,615 shares based on short interest data. This represents volume more than 141 times the typical daily average, indicating exceptionally heavy interest.
AEON's market capitalization is approximately $9.47 million, making it a micro-cap biotech stock with the volatility that often accompanies smaller pharmaceutical companies advancing clinical programs.
Recent Company Developments
The forced degradation results follow a string of positive data announcements for AEON. In August, the company reported expanded structural data supporting molecular similarity of ABP-450 to BOTOX and designated former FDA neuroscience leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer. The company also regained compliance with NYSE American listing standards in August after previously facing delisting notices.
AEON Biopharma is based in Newport Beach, California, and employs just five people according to its company profile, reflecting the lean operating structure typical of early-stage biotechs.